Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

157 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
State-of-the-Art Strategies for Targeting RET-Dependent Cancers.
Subbiah V, Yang D, Velcheti V, Drilon A, Meric-Bernstam F. Subbiah V, et al. Among authors: velcheti v. J Clin Oncol. 2020 Apr 10;38(11):1209-1221. doi: 10.1200/JCO.19.02551. Epub 2020 Feb 21. J Clin Oncol. 2020. PMID: 32083997 Free PMC article. Review.
Response to Cottu, Bozec, Basse, and Paoletti.
Zhang H, Han H, He T, Labbe KE, Hernandez AV, Chen H, Velcheti V, Stebbing J, Wong KK. Zhang H, et al. Among authors: velcheti v. J Natl Cancer Inst. 2021 Mar 1;113(3):344-345. doi: 10.1093/jnci/djaa214. J Natl Cancer Inst. 2021. PMID: 33404597 Free PMC article. No abstract available.
Precision therapy for RET-altered cancers with RET inhibitors.
Thein KZ, Velcheti V, Mooers BHM, Wu J, Subbiah V. Thein KZ, et al. Among authors: velcheti v. Trends Cancer. 2021 Dec;7(12):1074-1088. doi: 10.1016/j.trecan.2021.07.003. Epub 2021 Aug 12. Trends Cancer. 2021. PMID: 34391699 Free PMC article. Review.
Targeting the Atf7ip-Setdb1 Complex Augments Antitumor Immunity by Boosting Tumor Immunogenicity.
Hu H, Khodadadi-Jamayran A, Dolgalev I, Cho H, Badri S, Chiriboga LA, Zeck B, Lopez De Rodas Gregorio M, Dowling CM, Labbe K, Deng J, Chen T, Zhang H, Zappile P, Chen Z, Ueberheide B, Karatza A, Han H, Ranieri M, Tang S, Jour G, Osman I, Sucker A, Schadendorf D, Tsirigos A, Schalper KA, Velcheti V, Huang HY, Jin Y, Ji H, Poirier JT, Li F, Wong KK. Hu H, et al. Among authors: velcheti v. Cancer Immunol Res. 2021 Nov;9(11):1298-1315. doi: 10.1158/2326-6066.CIR-21-0543. Epub 2021 Aug 30. Cancer Immunol Res. 2021. PMID: 34462284 Free PMC article.
Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib.
Bauml JM, Li BT, Velcheti V, Govindan R, Curioni-Fontecedro A, Dooms C, Takahashi T, Duda AW, Odegaard JI, Cruz-Guilloty F, Jin L, Zhang Y, Anderson A, Skoulidis F. Bauml JM, et al. Among authors: velcheti v. Lung Cancer. 2022 Apr;166:270-278. doi: 10.1016/j.lungcan.2021.10.007. Epub 2021 Oct 19. Lung Cancer. 2022. PMID: 34838325 Free PMC article.
Neuroendocrine lineage commitment of small cell lung cancers can be leveraged into p53-independent non-cytotoxic therapy.
Biswas S, Kang K, Ng KP, Radivoyevitch T, Schalper K, Zhang H, Lindner DJ, Thomas A, MacPherson D, Gastman B, Schrump DS, Wong KK, Velcheti V, Saunthararajah Y. Biswas S, et al. Among authors: velcheti v. Cell Rep. 2023 Aug 29;42(8):113016. doi: 10.1016/j.celrep.2023.113016. Epub 2023 Aug 18. Cell Rep. 2023. PMID: 37597186 Free PMC article.
157 results